Gain Therapeutics Management
Management criteria checks 2/4
Gain Therapeutics' CEO is Matthias Alder, appointed in Sep 2022, has a tenure of 1.67 years. total yearly compensation is $1.08M, comprised of 41.3% salary and 58.7% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $61.94K. The average tenure of the management team and the board of directors is 1.9 years and 3.3 years respectively.
Key information
Matthias Alder
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 41.3% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.9yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$19m |
| Dec 31 2022 | US$1m | US$445k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | US$83k | -US$14m |
Compensation vs Market: Matthias's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Matthias's compensation has been consistent with company performance over the past year.
CEO
Matthias Alder (58 yo)
1.7yrs
Tenure
US$1,075,807
Compensation
Mr. Matthias Alder, LIC. IUR., LL M., served as Chief Operating Officer of Gain Therapeutics, Inc. since October 15, 2021 and serves as its President, Chief Executive Officer and Director from September 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 7.3yrs | US$94.85k | 4.88% $ 2.6m | |
| President | 1.7yrs | US$1.08m | 0.12% $ 61.9k | |
| Chief Financial Officer | less than a year | no data | no data | |
| GM & Chief Strategy Officer | 2.3yrs | US$550.05k | no data | |
| Senior Vice President of Research | 1.9yrs | no data | no data | |
| Senior Vice President of Technical Operations | 2.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.9yrs
Average Tenure
58yo
Average Age
Experienced Management: GANX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Chairman | 7.3yrs | US$94.85k | 4.88% $ 2.6m | |
| President | 1.7yrs | US$1.08m | 0.12% $ 61.9k | |
| Independent Director | 3.3yrs | US$81.85k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.3yrs | US$64.85k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$78.35k | 0% $ 0 | |
| Director | 3.8yrs | US$1.41m | 1.59% $ 842.3k | |
| Chairman of the Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | 5yrs | US$80.35k | 0.17% $ 87.9k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | 3.3yrs | US$69.85k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.5yrs | no data | no data |
3.3yrs
Average Tenure
62yo
Average Age
Experienced Board: GANX's board of directors are considered experienced (3.3 years average tenure).